Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Public ClinicalTrials.gov record NCT05268289. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticosteroids in Patients With Active Lupus Nephritis Class III-IV, +/- V
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Study identification
- NCT ID
- NCT05268289
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 81 participants
Conditions and interventions
Conditions
Interventions
- Iptacopan (part 1) Drug
- Iptacopan (part 2) Drug
- Placebo + standard of care Drug
- Iptacopan + placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 10, 2022 (Actual)
- Primary completion
- Mar 19, 2026 (Actual)
- Completion
- Oct 1, 2026 (Actual)
- Last update posted
- Oct 15, 2026
2022 – 2026
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ronald Reagan UCLA Medical Center | Los Angeles | California | 90095 | — |
| Loma Linda University | San Bernardino | California | 92408 | — |
| Olive View UCLA Medical Center | Sylmar | California | 91342 | — |
| University of Colorado Denver | Aurora | Colorado | 80045 | — |
| Royal Research Corp | Hollywood | Florida | 33021 | — |
| Nephrology Associates Of Central FL | Orlando | Florida | 32806 | — |
| Florida Kidney Physicians | Riverview | Florida | 33578 | — |
| Nep Assoc of Northern Illinois | Hinsdale | Illinois | 60521 | — |
| Wichita Community Clcl Onco Program | Wichita | Kansas | 67214 | — |
| Ochsner Health System | New Orleans | Louisiana | 70121 | — |
| Johns Hopkins Hospital | Baltimore | Maryland | 21287 | — |
| Stony Brook Internists PC | East Setauket | New York | 11733 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Temple University | Philadelphia | Pennsylvania | 19140 | — |
| Dallas Nephrology Associates | Dallas | Texas | 75204 | — |
| Prolato Clinical Research Center | Houston | Texas | 77054 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05268289, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05268289 live on ClinicalTrials.gov.